Patent ID: 9737599
Date: 2017-08-22
CPC Classifications: A61K,A61P,C07K,G01N

Claim:
1. A method for treating a B cell malignancy in a subject, said method comprising administering to a subject in need thereof a pharmaceutical composition comprising: (A) an effective amount of a first isolated antibody, or an antigen-binding fragment thereof, that specifically binds the extracellular domain of native human FcγRIIB with greater affinity than said antibody or fragment thereof binds native human FcγRIIA, wherein said first antibody comprises: (B) an effective amount of a second isolated antibody, or an antigen-binding fragment thereof, that specifically binds human CD20; and (C) a pharmaceutically acceptable carrier; wherein said effective amounts of said first and second antibodies or said fragments thereof cause said pharmaceutical composition to mediate a synergistically reduced tumor volume relative to the tumor volume reductions mediated by: